Drug Profile
Research programme: skin disorder therapeutics - Azitra
Alternative Names: AZT 03Latest Information Update: 28 May 2023
Price :
$50
*
At a glance
- Originator Azitra
- Class Antipsoriatics; Bacteria; Skin disorder therapies
- Mechanism of Action Interleukin 10 modulators; Microbiome modulators; S100 protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eczema; Ichthyosis; Psoriasis
Most Recent Events
- 28 May 2023 No recent reports of development identified for preclinical development in Eczema in USA (Topical, Ointment)
- 28 May 2023 No recent reports of development identified for preclinical development in Ichthyosis in USA (Topical, Ointment)
- 28 May 2023 No recent reports of development identified for research development in Psoriasis in USA (Topical, Ointment)